Precigen (PGEN) Competitors $4.76 -0.01 (-0.11%) As of 12:56 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PGEN vs. MRUS, CRSP, TGTX, ACAD, KRYS, CYTK, MENS, ADMA, PCVX, and AAPGShould you be buying Precigen stock or one of its competitors? The main competitors of Precigen include Merus (MRUS), CRISPR Therapeutics (CRSP), TG Therapeutics (TGTX), ACADIA Pharmaceuticals (ACAD), Krystal Biotech (KRYS), Cytokinetics (CYTK), Jyong Biotech (MENS), ADMA Biologics (ADMA), Vaxcyte (PCVX), and Ascentage Pharma Group International (AAPG). These companies are all part of the "pharmaceutical products" industry. Precigen vs. Its Competitors Merus CRISPR Therapeutics TG Therapeutics ACADIA Pharmaceuticals Krystal Biotech Cytokinetics Jyong Biotech ADMA Biologics Vaxcyte Ascentage Pharma Group International Precigen (NASDAQ:PGEN) and Merus (NASDAQ:MRUS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership. Do analysts rate PGEN or MRUS? Precigen presently has a consensus target price of $8.25, suggesting a potential upside of 71.34%. Merus has a consensus target price of $88.75, suggesting a potential upside of 33.67%. Given Precigen's higher possible upside, analysts clearly believe Precigen is more favorable than Merus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Precigen 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Merus 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 3.08 Which has more risk and volatility, PGEN or MRUS? Precigen has a beta of 1.82, meaning that its stock price is 82% more volatile than the S&P 500. Comparatively, Merus has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500. Do insiders and institutionals have more ownership in PGEN or MRUS? 33.5% of Precigen shares are held by institutional investors. Comparatively, 96.1% of Merus shares are held by institutional investors. 47.1% of Precigen shares are held by insiders. Comparatively, 3.7% of Merus shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the media favor PGEN or MRUS? In the previous week, Precigen had 1 more articles in the media than Merus. MarketBeat recorded 11 mentions for Precigen and 10 mentions for Merus. Merus' average media sentiment score of 1.31 beat Precigen's score of 0.77 indicating that Merus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precigen 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Merus 8 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is PGEN or MRUS more profitable? Merus has a net margin of -685.64% compared to Precigen's net margin of -2,868.66%. Merus' return on equity of -50.28% beat Precigen's return on equity.Company Net Margins Return on Equity Return on Assets Precigen-2,868.66% -842.83% -78.98% Merus -685.64%-50.28%-42.00% Which has higher valuation and earnings, PGEN or MRUS? Precigen has higher earnings, but lower revenue than Merus. Merus is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrecigen$3.92M366.00-$126.24M-$0.42-11.46Merus$56.23M89.31-$215.33M-$5.50-12.07 SummaryMerus beats Precigen on 9 of the 17 factors compared between the two stocks. Get Precigen News Delivered to You Automatically Sign up to receive the latest news and ratings for PGEN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PGEN vs. The Competition Export to ExcelMetricPrecigenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.43B$3.11B$5.75B$9.82BDividend YieldN/A2.28%6.66%4.48%P/E Ratio-11.4421.0082.2026.53Price / Sales366.00395.17531.05108.84Price / CashN/A43.5325.7028.92Price / Book-40.138.1010.476.55Net Income-$126.24M-$53.35M$3.28B$265.93M7 Day Performance4.90%-0.08%-0.17%-0.58%1 Month Performance188.32%9.38%10.19%6.25%1 Year Performance354.25%10.82%46.75%22.32% Precigen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PGENPrecigen4.2848 of 5 stars$4.76-0.1%$8.25+73.5%+332.7%$1.42B$3.92M-11.32190MRUSMerus3.0036 of 5 stars$65.84-0.4%$88.75+34.8%+30.0%$4.98B$36.13M-11.9737News CoveragePositive NewsCRSPCRISPR Therapeutics3.5985 of 5 stars$51.83-2.3%$71.60+38.1%+10.4%$4.71B$37.31M-9.55460Positive NewsAnalyst RevisionTGTXTG Therapeutics4.4241 of 5 stars$29.33+1.3%$46.25+57.7%+26.6%$4.65B$329M79.27290Positive NewsACADACADIA Pharmaceuticals4.0492 of 5 stars$25.99-0.9%$28.88+11.1%+54.9%$4.38B$957.80M19.54510News CoverageAnalyst RevisionKRYSKrystal Biotech4.8163 of 5 stars$147.70-2.0%$210.38+42.4%-23.6%$4.27B$290.52M30.02210Positive NewsCYTKCytokinetics4.1137 of 5 stars$35.33-5.4%$71.58+102.6%-13.1%$4.23B$85.74M-6.93250Trending NewsAnalyst ForecastInsider TradeOptions VolumeMENSJyong BiotechN/A$54.81-1.3%N/AN/A$4.17BN/A0.0031News CoveragePositive NewsADMAADMA Biologics4.014 of 5 stars$17.26-0.7%$27.67+60.3%-0.6%$4.12B$426.45M20.07530Positive NewsPCVXVaxcyte2.8065 of 5 stars$30.79+0.1%$136.50+343.3%-60.9%$4.00BN/A-7.49160News CoveragePositive NewsAAPGAscentage Pharma Group InternationalN/A$42.47+3.3%N/AN/A$3.95B$390.60M0.00600Positive News Related Companies and Tools Related Companies MRUS Competitors CRSP Competitors TGTX Competitors ACAD Competitors KRYS Competitors CYTK Competitors MENS Competitors ADMA Competitors PCVX Competitors AAPG Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PGEN) was last updated on 9/3/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Precigen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Precigen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
